Upload
freddy56
View
835
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Citation preview
MassBiotech 2010Janice T. Bourque
President & CEO
Massachusetts Biotechnology Council
BioStrategy Seminar Series Thursday, September 18, 2003
The Massachusetts Biotechnology Council is a non-profit industry association for Massachusetts biotechnology.
The MBC advances common goals of the Massachusetts biotechnology industry by:
• Providing joint activities and services• Influencing legislative and regulatory policies• Strengthening industry community & collaborations• Building public support for biotechnology
Massachusetts Biotechnology Council
Source: Ernst & Young, Beyond Borders: The Global Biotechnology Report 2002;Feinstein Kean Healthcare.
National Biotechnology Industry
• United States– 1,457 biotechnology companies (342 are public)
– Employing 191,000 people
– $28.5 billion revenue in 2001
– Life Sciences accounts 13% of GDP, by 2013 expected to be 22%
– $3.7 billion invested in biotech in 2002
Source: Massachusetts Technology Collaborative, 2002 Index of the Massachusetts Innovation Economy, 2003, MassBiotech 2010 report, MBC, 2002.
MA Biotechnology Industry• Massachusetts
– Over 280 biotech (53 public) companies employing approximately 30,000 individuals.
– $835 million in life sciences-related venture capital investments in 2001
– Over 122 colleges and universities
– The Massachusetts Biotechnology Council (MBC) is the oldest and second largest biotechnology association in the world.
– Biotech accounted for half of the new industrial jobs created in Massachusetts during the past six years.
– Biotech accounted for 27% of $8.5 billion spent by Massachusetts public companies on R&D, 15% of venture capital funds raised, and 18% of the patents filed.
– Massachusetts has 8% of the world’s clinical pipeline.
– The state receives highest NIH dollars per capita.
– $572.8 million invested in biotech in 2002.
• The Massachusetts Biotechnology Council (MBC), with the assistance of The Boston Consulting Group (BCG), conducted a study of the Massachusetts biotechnology industry and the broader life-sciences economic cluster.
• Report available - www.massbiotech2010.com
MassBiotech 2010 Report
Life Sciences Cluster Composed of Diverse & Interconnected Segments
HEALTH CAREHospitalsProviders
PayersHMOs
Public health organizations
Patients
PUBLIC INSTITUTIONSState officialsLocal officialsQuasi-publics
Public agenciesCommunity-based
organizations
EDUCATIONUniversities
Community collegesK-12 schools
OTHER SERVICESLaw firms
Real estateIT firms
AccountantsConstruction
Medical devices
BIOTECHHuman therapeuticsAgricultural biotech
Marine biotechEnvironmental biotech
PharmaceuticalsDiagnosticsBiodevices
SPECIALIZEDSUPPLIERS
Lab/ bio supplies & equip.Platform & tools companies
Contract manufacturingBioinformatics
CROs
BASIC RESEARCHAcademic research labs
Academic medical centers
FUNDING ENTITIESGovernment grants
Venture capital firmsFinancial institutions
Competitive Advantage MA Companies Cite Universities & Talent as Primary Sources
Source: MBC, BCG Biotech 2010 project interviews
2 2112
35
8
11
11
14
19
21
0
10
20
30
40
50
60
70
80
90
100
Proximity to major universities
Availability of scientists
Strength of partner industries
Proximity to other biotech companies
Quality of life
Availability of skilled technicians
Availability of spouse jobs
Leg./ reg. environment
Cost of laborOther
Personal
Quality supplier base
Average allocation of 100 points across potential sources of MA advantage
“We started here because our founders come from Massachusetts universities. We stay here because the best people
are here.”
“We started here because our founders come from Massachusetts universities. We stay here because the best people
are here.”
Weather
Geographic Distribution of MA Biotech Employment in 2001
Worcester
Woods Hole
BeverlyDanvers
Wilmington
West Bridgewater
Wareham
Fall River
Devens
Boxborough
Billerica
Agawam
Ashland
Bedford
Boston
BrightonCambridge
Canton
Charlestown
Framingham
Franklin
Hopkinton
Lexington
Marlborough
Maynard Medford
Milford
Natick
Needham
NewtonNorthborough
Norwood
Rockland
Waltham
Watertown
Wellesley
Westborough
Woburn
Number of employees
1,000
500
100
Andover
Source: Massachusetts Biotechnology Council, BCG Value Science Center
280
215
149
185
240
88
0
50
100
150
200
250
300
1991 1994 1996 1998 2000 2002
Year
Number of Companies
Growth by Number of Companies
+69%
+16%
+12%
+16%
+24%
Source : Massachusetts Biotechnology Council
Biotech Companies in MA
Biotech Employment in MA
30,000
7,682
23,596
15,572
12,171
16,872
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
1991 1994 1996 1998 2000 2002
Year
Number of Employees
Growth by Number of Employees
+58%
+8%
+40%
+27%
+28%
Source : Massachusetts Biotechnology Council
MA Biotech Employment Outpacing Total Industrial Job Growth
18
30
0
5
10
15
20
25
30
'96 '97 '98 '99 '00 '01
667 691
0
100
200
300
400
500
600
700
800
'96 '97 '98 '99 '00 '01
(K) (K)
Massachusetts Industrial Jobs
Massachusetts Biotechnology Jobs
1% per year
1% per year 10%
per year10%
per year
Source : Massachusetts Division of Employment and Training
Biotech is a Growth Engine for MA
(1) Base SIC 2833-36, 3826, 8731 adjusted for individual companiesSource: PWC Money Tree Survey; BCG Value Science Center; United States Patent and Trademark Office classes 424, 435,
514, 532-570, 800
280
600
0
100
200
300
400
500
600
700
'96 '97 '98 '99 '00 '01
Venture-capital funds raised by Massachusetts biotechnology companies
16% per year
16% per year
840
2,300
0
500
1,000
1,500
2,000
2,500
'96 '97 '98 '99 '00 '01
R&D spending by Massachusetts biotechnology companies(1)
22% per year
22% per year
328
681
0
100
200
300
400
500
600
700
800
'96 '97 '98 '99 '00 '01
Biotechnology patents granted to Massachusetts
companies and universities
16% per year
16% per year
($M) (K)(K)
MA Companies Own Over 8% of Global Clinical Development Pipeline
State
Note: State attribution based on headquarters location of product’s primary owner (1) Pipeline includes large and small molecule drugs, diagnostic tests and biodevices
Source: Biospace Clinical Competitive Intelligence Systems (CCIS) database, September 2002
Number ofproducts in pipeline
470
201 196145
218
0%
5%
10%
15%
20%
CA MA NJ NY PA05010015020025030035040045050017.5%
8.1%7.5% 7.3%
5.4%
Number of FDA-Approved MA Biotech Products Expected to More Than Double by 2005
Expected growth of FDA-approved Massachusetts Biotechnology products
2002 2005 2010
~40
~90
~130
Development phaseDevelopment phase
Phase IPhase IIPhase IIIApproval pending
Current number Current number of productsof products
63734823
Probability of Probability of successsuccess(1)(1)
21%31%59%91%
Time to Time to marketmarket(1)(1)
~6 years~5 years~3 years~1 year
Expected outputExpected output
13 compounds by 200823 compounds by 200728 compounds by 200521 compounds by 2003
(1) Based on average figures for new chemical entities (NCEs); BCG analysis; Tufts Center for the Study of Drug DevelopmentSource: Biospace CCIS database; “A Revolution in R&D,” BCG, November, 2001; BCG analysis
MA Biotech In-State Capabilities
(1) Clinical development structure in state(2) Commercial manufacturing onlyNote: Sample is 134 human therapeutics companies Source: Massachusetts Biotechnology Council Survey 2002, BCG analysis
CommercialResearch Development(1) Manufacturing(2)
108
57
8
9
10
7
2611
153
232
24
MAcompanies
Out-of-state companieswith MA locations
Activity in Massachusetts
Activity in outside Massachusetts
0
2
4
6
8
10
12
14
16
18
20
1991 1996 2001 2005 2010
Opportunity to Create Nearly 100K Jobs
Note: 2001 baseline: 30K biotech jobs and ~70K indirect jobs= ~100K total jobs Source: Bio E&Y 2000 Report; MBC 2002 survey; BCG Analysis; Economic Model
MA share of U.S. biotech jobs 1991-2010
MA share of biotech jobs (%)
Lose ground• MA share erosion
continues
Increase share• MA strengthens
its #2 position
Unleash potential• MA closes gap
with CA
11
22
33
~150K new jobs
~90K new jobs
~20K new jobs
Industry Challenges & Opportunities
• Big Pharma moving to the state
• Keeping more pilot plant manufacturing in state
• State marketing campaign– Massachusetts It’s All Here
• Political engagement
• Increased interactions with Washington– NIH
– CDC
– FDA
– Department of Defense
MBC Initiatives• Economic Development
– “Team” Massachusetts approach– Physical A&E– Permitting & Zoning– Site Identification– Community Outreach & Networking
• Education – Science standards– Teacher training– High school lab equipment
• Workforce Training– Project Management– Clinical Trials for Doctors– Biotech 101
MBC Initiatives• Technology Transfer
– Improving process
– Addressing conflicts of interest
• Clinical Trials– Expansion of # and type of clinical trials in MA
• Policy/Public Affairs– Stems cells
– Permitting
– Tax policy
– Price controls
– Restrictive access to therapies
• Communications– Public understanding of biotech
MassBiotech 2010Janice T. Bourque
President & CEO
Massachusetts Biotechnology Council
BioStrategy Seminar Series Thursday, September 18, 2003